Get started
Author

A. Inoue

Observed name: A Inoue
ORCID: 0000-0002-2954-2722
Observed ORCID: 0000-0002-2954-2722
OpenAlex ID: A5065197178
Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
2011 · A. Inoue, K. Kobayashi, et al. · Journal of Clinical Oncology · 37
A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).
2011 · N. Yamamoto, N. Katakami, et al. · Journal of Clinical Oncology · 25
First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study).
2010 · Y. Minegishi, M. Maemondo, et al. · Journal of Clinical Oncology · 20
9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
2009 · A. Inoue, K. Kobayashi, et al. · European Journal of Cancer Supplements · 16
A Phase I/II Study of Alk Inhibitor CH5424802 in Patients With Alk-Positive Nsclc; Safety and Efficacy Interim Results of the Phase II Portion
2012 · M. Nishio, K. Kiura, et al. · Annals of Oncology · 15
PDF
Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP)
2008 · S. Morita, T. Hirashima, et al. · Journal of Clinical Oncology · 11
Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
2018 · M. Seike, A. Inoue, et al. · Annals of Oncology · 10
PP47 First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group
2009 · Y. Minegishi, A. Inoue, et al. · European Journal of Cancer Supplements · 4
A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC)
2005 · K. Usui, A. Inoue, et al. · Journal of Clinical Oncology · 4
First-line gefitinib for poor PS patients with EGFR mutations
2008 · K. Kobayashi, A. Inoue, et al. · Journal of Clinical Oncology · 3
3072 Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy
2015 · K. Kasahara, K. Kiura, et al. · European Journal of Cancer · 2
The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.
2010 · A. Inoue, M. Maemondo, et al. · Journal of Clinical Oncology · 1
Randomized, phase II trial comparing carboplatin (C) and tri-weekly paclitaxel (tP) with C and weekly paclitaxel (wP) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC)
2008 · M. Maemondo, A. Inoue, et al. · Journal of Clinical Oncology · 1
Phase I trial of bi-weekly docetaxel combined with carboplatin for patients with non-small cell lung cancer
2004 · A. Inoue, T. Ishida, et al. · Journal of Clinical Oncology · 1
A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
2019 · K. Baba, H. Tanaka, et al. · Annals of Oncology
3064 NEJ016: Phase II study of carboplatin and weekly paclitaxel plus bevacizumab followed by bevacizumab for highly selected elderly non-squamous non-small cell lung cancer patients
2015 · T. Harada, S. Miura, et al. · European Journal of Cancer
Final Analysis of Randomized Phase II Trial of Carboplatin Combined with Weekly Paclitaxel (CP) and Docetaxel Alone (D) in Elderly Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC): NJLCG 0801
2012 · T. Harada, M. Maemondo, et al. · Annals of Oncology
Final results of a phase II trial of S-1 with biweekly docetaxel for non-small cell lung cancer previously treated with platinum-based chemotherapy (NJLCG0701).
2010 · O. Ishimoto, T. Sakakibara, et al. · Journal of Clinical Oncology
9070 Phase II trial of S-1 with bi-weekly docetaxel for non-small-cell lung cancer previously treated with platinum-based chemotherapy: a North Japan Lung Cancer Study Group (NJLCG0701)
2009 · M. Maemondo, O. Ishimoto, et al. · European Journal of Cancer Supplements
感受性egfr変異を有する非小細胞肺癌(nsclc)の一次治療のためのパクリタキセル(txl)を加えたカルボプラチン(cbdca)とゲフィチニブを比較した無作為化第iii相試験:nej002研究
2009 · Akihiko Genma, Shinroku Morita, et al. · European Journal of Cancer Supplements
46 A phase II trial of biweekly docetaxel combined with carboplatinfor patients with advanced non-small cell lung cancer
2005 · O. Ishimoto, S. Sugawara, et al. · Lung Cancer
417 Patients Retreated With Nedaplatin After Development of Carboplatin Allergy
2004 · S. Suzuki, Y. Kishigami, et al. · International Journal of Gynecological Cancer
Concurrent cisplatin/etoposide (PE) and twice-daily thoracic radiotherapy (BID TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC)
2000 · A Inoue, K Kubota, et al. · Lung Cancer
Works count: 23
Citation count: 150
H-index: 7
I10-index: 7
Year
Topic
Type